Association between serum fibroblast growth factor-23 concentration and development of hyperphosphatemia in normophosphatemic dogs with chronic kidney disease
Journal of Veterinary Internal Medicine2021Vol. 35(5), pp. 2296–2305
Citations Over Time
Abstract
Increased FGF-23 concentration in normophosphatemic dogs with CKD was associated with significant risk of development of hyperphosphatemia, independent of CKD stage, and of the progression of CKD. Future research focusing on whether interventions that decrease FGF-23 secretion will slow the development of hyperphosphatemia and CKD progression is needed.
Related Papers
- → Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers(2003)689 cited
- → Hyperphosphatemia of chronic kidney disease(2008)433 cited
- → A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway(2017)
- Dietary Phosphorus and FGF23: Is More Restriction Better?(2019)
- → Sustained Phosphate Reduction Assessed by Phosphate Area under the Curve with Tenapanor Is Associated with Reduced Fibroblast Growth Factor 23 in Patients with CKD and Hyperphosphatemia on Dialysis(2024)